Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth

Michael H. Muders, Pawan K. Vohra, Shamit K. Dutta, Enfeng Wang, Yasuhiro Ikeda, Ling Wang, D. Gomika Udugamasooriya, Adnan Memic, Chamila N. Rupashinghe, Gustavo B. Baretton, Daniela E. Aust, Silke Langer, Kaustubh Datta, Michael Simons, Mark R. Spaller, Debabrata Mukhopadhyay

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose: Various studies have shown the importance of the GAIP interacting protein, COOH-terminus (GIPC, also known as Synectin) as a central adaptor molecule in different signaling pathways and as an important mediator of receptor stability. GIPC/Synectin is associated with different growth-promoting receptors such as insulin-like growth factor receptor I (IGF-IR) and integrins. These interactions were mediated through its PDZ domain. GIPC/Synectin has been shown to be overexpressed in pancreatic and breast cancer. The goal of this study was to show the importance of GIPC/Synectin in pancreatic cancer growth and to evaluate a possible therapeutic strategy by using a GIPC-PDZ domain inhibitor. Furthermore, the effect of targeting GIPC on the IGF-I receptor as one of its associated receptors was tested. Experimental Design: The in vivo effects of GIPC/Synectin knockdown were studied after lentiviral transduction of luciferase-expressing pancreatic cancer cells with short hairpin RNA against GIPC/Synectin. Additionally, a GIPC-PDZ - targeting peptide was designed. This peptide was tested for its influence on pancreatic cancer growth in vitro and in vivo. Results: Knockdown of GIPC/Synectin led to a significant inhibition of pancreatic adenocarcinoma growth in an orthotopic mouse model. Additionally, a cell-permeable GIPC-PDZ inhibitor was able to blocktu mor growth significantly without showing toxicity in a mouse model. Targeting GIPC was accompanied by a significant reduction in IGF-IR expression in pancreatic cancer cells. Conclusions: Our findings show that targeting GIPC/Synectin and its PDZ domain inhibits pancreatic carcinoma growth and is a potential strategy for therapeutic intervention of pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)4095-4103
Number of pages9
JournalClinical Cancer Research
Volume15
Issue number12
DOIs
StatePublished - Jun 15 2009

Fingerprint

Pancreatic Neoplasms
PDZ Domains
Growth
Neoplasms
IGF Type 1 Receptor
Peptides
Luciferases
Integrins
Small Interfering RNA
Adenocarcinoma
Research Design
Breast Neoplasms
Therapeutics
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Muders, M. H., Vohra, P. K., Dutta, S. K., Wang, E., Ikeda, Y., Wang, L., ... Mukhopadhyay, D. (2009). Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. Clinical Cancer Research, 15(12), 4095-4103. https://doi.org/10.1158/1078-0432.CCR-08-2837

Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. / Muders, Michael H.; Vohra, Pawan K.; Dutta, Shamit K.; Wang, Enfeng; Ikeda, Yasuhiro; Wang, Ling; Udugamasooriya, D. Gomika; Memic, Adnan; Rupashinghe, Chamila N.; Baretton, Gustavo B.; Aust, Daniela E.; Langer, Silke; Datta, Kaustubh; Simons, Michael; Spaller, Mark R.; Mukhopadhyay, Debabrata.

In: Clinical Cancer Research, Vol. 15, No. 12, 15.06.2009, p. 4095-4103.

Research output: Contribution to journalArticle

Muders, MH, Vohra, PK, Dutta, SK, Wang, E, Ikeda, Y, Wang, L, Udugamasooriya, DG, Memic, A, Rupashinghe, CN, Baretton, GB, Aust, DE, Langer, S, Datta, K, Simons, M, Spaller, MR & Mukhopadhyay, D 2009, 'Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth', Clinical Cancer Research, vol. 15, no. 12, pp. 4095-4103. https://doi.org/10.1158/1078-0432.CCR-08-2837
Muders MH, Vohra PK, Dutta SK, Wang E, Ikeda Y, Wang L et al. Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. Clinical Cancer Research. 2009 Jun 15;15(12):4095-4103. https://doi.org/10.1158/1078-0432.CCR-08-2837
Muders, Michael H. ; Vohra, Pawan K. ; Dutta, Shamit K. ; Wang, Enfeng ; Ikeda, Yasuhiro ; Wang, Ling ; Udugamasooriya, D. Gomika ; Memic, Adnan ; Rupashinghe, Chamila N. ; Baretton, Gustavo B. ; Aust, Daniela E. ; Langer, Silke ; Datta, Kaustubh ; Simons, Michael ; Spaller, Mark R. ; Mukhopadhyay, Debabrata. / Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 12. pp. 4095-4103.
@article{5f683424d9fb47a5925e4aba6f7a9056,
title = "Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth",
abstract = "Purpose: Various studies have shown the importance of the GAIP interacting protein, COOH-terminus (GIPC, also known as Synectin) as a central adaptor molecule in different signaling pathways and as an important mediator of receptor stability. GIPC/Synectin is associated with different growth-promoting receptors such as insulin-like growth factor receptor I (IGF-IR) and integrins. These interactions were mediated through its PDZ domain. GIPC/Synectin has been shown to be overexpressed in pancreatic and breast cancer. The goal of this study was to show the importance of GIPC/Synectin in pancreatic cancer growth and to evaluate a possible therapeutic strategy by using a GIPC-PDZ domain inhibitor. Furthermore, the effect of targeting GIPC on the IGF-I receptor as one of its associated receptors was tested. Experimental Design: The in vivo effects of GIPC/Synectin knockdown were studied after lentiviral transduction of luciferase-expressing pancreatic cancer cells with short hairpin RNA against GIPC/Synectin. Additionally, a GIPC-PDZ - targeting peptide was designed. This peptide was tested for its influence on pancreatic cancer growth in vitro and in vivo. Results: Knockdown of GIPC/Synectin led to a significant inhibition of pancreatic adenocarcinoma growth in an orthotopic mouse model. Additionally, a cell-permeable GIPC-PDZ inhibitor was able to blocktu mor growth significantly without showing toxicity in a mouse model. Targeting GIPC was accompanied by a significant reduction in IGF-IR expression in pancreatic cancer cells. Conclusions: Our findings show that targeting GIPC/Synectin and its PDZ domain inhibits pancreatic carcinoma growth and is a potential strategy for therapeutic intervention of pancreatic cancer.",
author = "Muders, {Michael H.} and Vohra, {Pawan K.} and Dutta, {Shamit K.} and Enfeng Wang and Yasuhiro Ikeda and Ling Wang and Udugamasooriya, {D. Gomika} and Adnan Memic and Rupashinghe, {Chamila N.} and Baretton, {Gustavo B.} and Aust, {Daniela E.} and Silke Langer and Kaustubh Datta and Michael Simons and Spaller, {Mark R.} and Debabrata Mukhopadhyay",
year = "2009",
month = "6",
day = "15",
doi = "10.1158/1078-0432.CCR-08-2837",
language = "English (US)",
volume = "15",
pages = "4095--4103",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth

AU - Muders, Michael H.

AU - Vohra, Pawan K.

AU - Dutta, Shamit K.

AU - Wang, Enfeng

AU - Ikeda, Yasuhiro

AU - Wang, Ling

AU - Udugamasooriya, D. Gomika

AU - Memic, Adnan

AU - Rupashinghe, Chamila N.

AU - Baretton, Gustavo B.

AU - Aust, Daniela E.

AU - Langer, Silke

AU - Datta, Kaustubh

AU - Simons, Michael

AU - Spaller, Mark R.

AU - Mukhopadhyay, Debabrata

PY - 2009/6/15

Y1 - 2009/6/15

N2 - Purpose: Various studies have shown the importance of the GAIP interacting protein, COOH-terminus (GIPC, also known as Synectin) as a central adaptor molecule in different signaling pathways and as an important mediator of receptor stability. GIPC/Synectin is associated with different growth-promoting receptors such as insulin-like growth factor receptor I (IGF-IR) and integrins. These interactions were mediated through its PDZ domain. GIPC/Synectin has been shown to be overexpressed in pancreatic and breast cancer. The goal of this study was to show the importance of GIPC/Synectin in pancreatic cancer growth and to evaluate a possible therapeutic strategy by using a GIPC-PDZ domain inhibitor. Furthermore, the effect of targeting GIPC on the IGF-I receptor as one of its associated receptors was tested. Experimental Design: The in vivo effects of GIPC/Synectin knockdown were studied after lentiviral transduction of luciferase-expressing pancreatic cancer cells with short hairpin RNA against GIPC/Synectin. Additionally, a GIPC-PDZ - targeting peptide was designed. This peptide was tested for its influence on pancreatic cancer growth in vitro and in vivo. Results: Knockdown of GIPC/Synectin led to a significant inhibition of pancreatic adenocarcinoma growth in an orthotopic mouse model. Additionally, a cell-permeable GIPC-PDZ inhibitor was able to blocktu mor growth significantly without showing toxicity in a mouse model. Targeting GIPC was accompanied by a significant reduction in IGF-IR expression in pancreatic cancer cells. Conclusions: Our findings show that targeting GIPC/Synectin and its PDZ domain inhibits pancreatic carcinoma growth and is a potential strategy for therapeutic intervention of pancreatic cancer.

AB - Purpose: Various studies have shown the importance of the GAIP interacting protein, COOH-terminus (GIPC, also known as Synectin) as a central adaptor molecule in different signaling pathways and as an important mediator of receptor stability. GIPC/Synectin is associated with different growth-promoting receptors such as insulin-like growth factor receptor I (IGF-IR) and integrins. These interactions were mediated through its PDZ domain. GIPC/Synectin has been shown to be overexpressed in pancreatic and breast cancer. The goal of this study was to show the importance of GIPC/Synectin in pancreatic cancer growth and to evaluate a possible therapeutic strategy by using a GIPC-PDZ domain inhibitor. Furthermore, the effect of targeting GIPC on the IGF-I receptor as one of its associated receptors was tested. Experimental Design: The in vivo effects of GIPC/Synectin knockdown were studied after lentiviral transduction of luciferase-expressing pancreatic cancer cells with short hairpin RNA against GIPC/Synectin. Additionally, a GIPC-PDZ - targeting peptide was designed. This peptide was tested for its influence on pancreatic cancer growth in vitro and in vivo. Results: Knockdown of GIPC/Synectin led to a significant inhibition of pancreatic adenocarcinoma growth in an orthotopic mouse model. Additionally, a cell-permeable GIPC-PDZ inhibitor was able to blocktu mor growth significantly without showing toxicity in a mouse model. Targeting GIPC was accompanied by a significant reduction in IGF-IR expression in pancreatic cancer cells. Conclusions: Our findings show that targeting GIPC/Synectin and its PDZ domain inhibits pancreatic carcinoma growth and is a potential strategy for therapeutic intervention of pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=67449138838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449138838&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-2837

DO - 10.1158/1078-0432.CCR-08-2837

M3 - Article

C2 - 19509165

AN - SCOPUS:67449138838

VL - 15

SP - 4095

EP - 4103

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -